In MM, BCL6 might underwent abnormal reactivation, particularly in specific subtypes such as those with low CD138 expression or IL-6-dependent cells, where heightened expression was intimately linked to tumor cell proliferation, survival, and resistance to treatment (32, 55, 56). This evidence concerns the gene BCL6 and Miyoshi myopathy.